Scientists test new drug cocktail in fight against tough blood cancers
NCT ID NCT01846390
Summary
This early-stage study aimed to find the safest dose of a new four-drug combination (romidepsin plus GDP) for patients with two types of aggressive lymphoma that had returned after prior treatment. The main goal was to determine how much of the new drug could be added without causing severe, intolerable side effects. Researchers tested increasing doses in small groups of up to 21 patients to identify the maximum amount that could be tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
Regional Health Authority B, Zone 2
Saint John, New Brunswick, E2L 4L2, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.